POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.55 CHF | +2.43% |
|
+1.90% | +68.66% |
| 03-12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| 03-12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,371 | 842.2 | 620.9 | 997.7 | - | - |
| Enterprise Value (EV) 1 | 4,264 | 836.4 | 620.9 | 1,092 | 1,129 | 1,156 |
| P/E ratio | 90 x | 107 x | -12.1 x | -100 x | 64.5 x | 26.4 x |
| Yield | 0.22% | - | - | - | 0.15% | 0.85% |
| Capitalization / Revenue | 15.5 x | 3 x | 1.91 x | 2.86 x | 2.45 x | 2.03 x |
| EV / Revenue | 15.1 x | 2.98 x | 1.91 x | 3.13 x | 2.78 x | 2.35 x |
| EV / EBITDA | 50.3 x | 21.6 x | -103 x | 41.7 x | 18 x | 11.1 x |
| EV / FCF | -257 x | -11.4 x | - | -23.6 x | -86.2 x | -95.6 x |
| FCF Yield | -0.39% | -8.76% | - | -4.23% | -1.16% | -1.05% |
| Price to Book | 10.1 x | 2 x | - | 2.72 x | 2.58 x | 2.4 x |
| Nbr of stocks (in thousands) | 33,031 | 32,938 | 32,944 | 32,970 | - | - |
| Reference price 2 | 132.3 | 25.57 | 18.85 | 30.26 | 30.26 | 30.26 |
| Announcement Date | 22-03-15 | 23-03-14 | 24-03-12 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 223 | 282.1 | 281 | 324.9 | 348.7 | 406.6 | 491.9 |
| EBITDA 1 | - | 84.8 | 38.67 | -6 | 26.18 | 62.63 | 104.3 |
| EBIT 1 | - | 64.2 | 12.61 | -36.47 | -4.97 | 28.46 | 62.8 |
| Operating Margin | - | 22.76% | 4.49% | -11.23% | -1.43% | 7% | 12.77% |
| Earnings before Tax (EBT) 1 | - | 59.85 | 7.567 | -58.24 | -12.55 | 17.7 | 41.6 |
| Net income 1 | 31.34 | 47.26 | 7.767 | -51.44 | -12.22 | 14.9 | 38.43 |
| Net margin | 14.05% | 16.75% | 2.76% | -15.83% | -3.5% | 3.66% | 7.81% |
| EPS 2 | - | 1.470 | 0.2400 | -1.560 | -0.3017 | 0.4689 | 1.145 |
| Free Cash Flow 1 | - | -16.61 | -73.3 | - | -46.2 | -13.1 | -12.1 |
| FCF margin | - | -5.89% | -26.09% | - | -13.25% | -3.22% | -2.46% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.2909 | - | - | - | 0.0444 | 0.2557 |
| Announcement Date | 21-03-15 | 22-03-15 | 23-03-14 | 24-03-12 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 135.1 | 133.7 | 147.3 | 131.8 | 191.5 | 131.8 | 212.6 |
| EBITDA 1 | 39.89 | 26.71 | - | -19.39 | 13.4 | 0.7 | 26.8 |
| EBIT 1 | - | 15.48 | - | - | -2.004 | -14.9 | 10.7 |
| Operating Margin | - | 11.58% | - | - | -1.05% | -11.31% | 5.03% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income 1 | - | 10.25 | -2.48 | -34.27 | - | -19.8 | 8.7 |
| Net margin | - | 7.67% | -1.68% | -25.99% | - | -15.02% | 4.09% |
| EPS | - | 0.3100 | - | -1.040 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21-08-17 | 22-08-18 | 23-03-14 | 23-08-15 | 24-03-12 | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 93.9 | 132 | 159 |
| Net Cash position 1 | - | 107 | 5.8 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | 3.587 x | 2.103 x | 1.522 x |
| Free Cash Flow 1 | - | -16.6 | -73.3 | - | -46.2 | -13.1 | -12.1 |
| ROE (net income / shareholders' equity) | - | 16.7% | 1.84% | - | -3.91% | 4.13% | 10.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 13.10 | 12.80 | - | 11.10 | 11.70 | 12.60 |
| Cash Flow per Share 2 | - | 1.780 | 0.1700 | - | 0.5800 | 1.500 | 2.740 |
| Capex 1 | - | 74 | 78.8 | - | 57.3 | 59.4 | 55.5 |
| Capex / Sales | - | 26.22% | 28.03% | - | 16.42% | 14.6% | 11.28% |
| Announcement Date | 21-03-15 | 22-03-15 | 23-03-14 | 24-03-12 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.26
EUR
Average target price
22.24
EUR
Spread / Average Target
-26.52%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +68.66% | 1.07B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PPGN Stock
- Financials PolyPeptide Group AG
